Volume 70, Issue 3, Pages e72-e74 (September 2016)

Slides:

Advertisements

Similar presentations

Volume 58, Issue 5, Pages (November 2010)

Advertisements

Volume 72, Issue 3, Pages (September 2017)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

European Urology Focus

Volume 63, Issue 2, Pages (February 2013)

Volume 70, Issue 1, Pages (July 2016)

Testosterone Therapy in Men With Prostate Cancer

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Volume 71, Issue 2, Pages (February 2017)

Volume 57, Issue 3, Pages e22-e23 (March 2010)

Volume 52, Issue 3, Pages (September 2007)

Volume 69, Issue 1, Pages (January 2016)

Histologic Grading of Noninvasive Papillary Urothelial Neoplasms

Volume 63, Issue 3, Pages e39-e40 (March 2013)

Volume 54, Issue 4, Pages (October 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,

Volume 73, Issue 5, Pages (May 2018)

Volume 64, Issue 3, Pages (September 2013)

Prostate Cancer Epidemic in Sight?

Volume 58, Issue 1, Pages (July 2010)

Re: Marcus G. Cumberbatch, Matteo Rota, James W. F

John P. Mulhall, Francesco Montorsi European Urology

Volume 63, Issue 4, Pages e53-e56 (April 2013)

Volume 68, Issue 5, Pages (November 2015)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 68, Issue 1, Pages 5-7 (July 2015)

Volume 66, Issue 4, Pages (October 2014)

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 50, Issue 4, Pages (October 2006)

Volume 54, Issue 6, Pages (December 2008)

Volume 70, Issue 1, Pages (July 2016)

Volume 56, Issue 2, Pages (August 2009)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Prostate Cancer Epidemic in Sight?

Volume 50, Issue 3, Pages (September 2006)

Volume 59, Issue 3, Pages e7-e8 (March 2011)

Volume 70, Issue 1, Pages e27-e28 (July 2016)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

Volume 56, Issue 1, Pages (July 2009)

Volume 68, Issue 6, Pages e134-e135 (December 2015)

Volume 64, Issue 6, Pages (December 2013)

TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential Liang Cheng, Rodolfo Montironi,

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

Volume 55, Issue 6, Pages (June 2009)

Re: Christine McKillop

2005 Update on Pathology of Prostate Biopsies with Cancer

Testicular Cancer Variations in Time and Space in Europe

Volume 66, Issue 6, Pages (December 2014)

Volume 63, Issue 2, Pages (February 2013)

Volume 54, Issue 4, Pages (October 2008)

European Urology is “Your” Journal

The Start-Up of the Platinum Journal: A Fascinating Challenge

Volume 53, Issue 6, Pages (June 2008)

Volume 54, Issue 1, Pages (July 2008)

Volume 53, Issue 2, Pages (February 2008)

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Annika Berntsen, Poul F. Geertsen, Inge Marie Svane European Urology

Joaquim Bellmunt European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

2005 Update on Pathology of Prostate Biopsies with Cancer

Presentation transcript:

Volume 70, Issue 3, Pages e72-e74 (September 2016) Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912–4 Francesco Piva, Matteo Santoni, Marina Scarpelli, Alberto Briganti, Antonio Lopez-Beltran, Liang Cheng, Rossana Berardi, Francesco Montorsi, Rodolfo Montironi European Urology Volume 70, Issue 3, Pages e72-e74 (September 2016) DOI: 10.1016/j.eururo.2016.02.049 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Connection between PBRM1 mutational status and programmed death ligand 1 (PD-L1) expression. (a) MiR-34a transcription is induced by the p53 transcription factor that, in turn, can be activated by BAF180, encoded by PBMR1. (b) Mutations that impair BAF180 by p53 could downregulate miR-34a, the consequence being that PD-L1 expression in cancer cells would no longer be silenced. PD-L1=programmed death ligand 1. European Urology 2016 70, e72-e74DOI: (10.1016/j.eururo.2016.02.049) Copyright © 2016 European Association of Urology Terms and Conditions